The U.S. Food and Drug Administration has approved Sanofi and Regeneron’s Dupixent (dupilumab) for the treatment of children (aged 2 to 11 years) with chronic spontaneous urticaria (CSU).
This article was originally published on MedicalXpress.com
FDA approves Dupixent for chronic spontaneous urticaria in young children
You may also be interested in:
The Latest
Setting Boundaries: Nurturing a Healthy Partnership
What Are Boundaries? As the word portrays, boundaries in a relationship help each person establish expectations with their partner. Boundaries can help you communicate what you are comfortable with and what you are willing to […]
The Latest
Restoring Kitchen Efficiency with Oven Repair in Barrie
Preparing home-cooked meals is a great way to bring family together and maintain a healthy lifestyle. However, when your oven or range stops working properly, your entire cooking routine can come to a grinding halt. […]
Food
Transform Your Kitchen: Mastering Allergy-Safe Cooking Through Ingenious Ingredient Swaps
By Daniel Zane Bryant, author of “Living with Food Allergies: A Complete Lifestyle Guide” (available on Amazon at https://www.amazon.com/dp/B0G2BcGB2K) Navigating food allergies might initially feel overwhelming, yet it presents an exciting opportunity to reimagine familiar […]
Read More:
-
Researchers from the Wits Vaccines and Infectious Diseases Analytics (Wits VIDA) Research Unit at the University of the Witwatersrand (Wits) have played a leading role [...]
-
Sugar restriction during the first 1,000 days after conception may significantly reduce a person’s risk of developing Alzheimer’s by up to 46%. Those are the [...]
-
A cell therapy called deramiocel could slow muscle weakening in boys and young men with advanced Duchenne muscular dystrophy (DMD) and may also slow heart [...]
